WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60


Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
            Best Paper Award :
Dr. Muhammad Baqir MR Fakhrildin
Download Article: Click Here


Track Your Article



Prasanth Vas Sahu*, B.A. Vishwanath, Bharathi Kalyanam, Phool Kumari Shah,
Pravin Rajbanshi, Praveen Kumar and Brunda M.S


Background: Elevated levels of blood lipids are well documented risk factors for cardiovascular disease. Current classification schemes and treatment levels for hyperlipidemia are based on the National Cholesterol Education Panel’s (NCEP) Adult Treatment Program-3 (ATP-III) guidelines. Globally, a third of ischaemic heart disease is attributable to high cholesterol. Overall, raised cholesterol is estimated to cause 2.6 million deaths (4.5% of total) and 29.7 million disability adjusted life years (DALYS), or 2.0% of total DALYS. Raised total cholesterol is a major cause of disease burden in both the developed and developing world as a risk factor for Ischemic heart disease and stroke. Statins are the preferred class of drugs to lower elevated low density lipoprotein cholesterol (LDL-C). New guidelines from ATP-IV are expected to be released in the near future, but in the meantime physicians are faced with uncertainty about how low to target LDL-C, whether to pharmacologically treat high density lipoprotein cholesterol (HDL-C) and triglyceride (TG) levels and how best to achieve target goals. Study on drug use evaluation on a tertiary care hospital was conducted. Objectives: The comparison of Hyperlipidemic drugs such as ATORVASTATIN and ROSUVASTATIN by analysing the appropriateness of prescription with special reference to:  Selection of antihyperlipidemic drugs (ATORVASTATIN and ROSUVASTATIN) in various clinical conditions  Concomitant drugs used  Switched therapy  Frequency of administration  Drug-wise distribution  Lab data collection Methods and Methodology: comparison of antihyperlipidemic drugs in a tertiary care hospital is a retrospective and prospective study, patients who were satisfying the inclusion criteria was enrolled into the study conducted for the period of 6 months. Data collection form and other relevant source from Medical Record department are used as source of data and materials. Results: 150 hyperlipidemic cases were examined and 59% were male and 41 % female. Where ATORVASTATIN 50.66% and ROSUVASTATIN 49.33% were used, according to age wise distribution hyperlipidemic patients was found as following, 31-40 years 7.33%, 41-40 years 14%, 51-60 years 25.33%, 61-70 years 36%, 71-80 years 10.66%, 81-90 years 6.66%. where we found age between 61-70 years were more hyperlipidemic patients. Comparison between two drugs we found lipid lowering data which shows the effectiveness of the drugs where 5mg of ROSUVASTATIN shows 41% LDL-C reduction whereas ATORVASTATIN 10mg shows 38% LDL-C reduction, similarly 10mg ROSUVASTATIN shows 47% LDL-C reduction and atorvastatin 20mg shows 41% LDL-C reduction, 20mg ROSUVASTATIN shows 55% LDL-C reduction and 40mg ATORVASTATIN shows 47% LDL-C reduction, 40mg ROSUVASTATIN shows 63% and 80mg ATORVASTATIN shows 55% LDL-C reduction. Which shows ROSUVASTATIN is more effective than ATORVASTATIN. Comparison between two drugs we got p-value of ROSUVASTATIN is 0.021178 and ATORVASTATIN is 0.44964. which shows the effectiveness of the drugs, as per our study we found ROSUVASTATIN is more effective than ATORVASTATIN. Conclusion: To conclude, although this study had a small sample size it gave us an overall idea about the comparative study on lipid lowering efficacy and safety profile of ATORVASTATIN versus ROSUVASTATIN in hyperlipidemia in a Tertiary Care Hospital. Despite of the fact that patient with Renal Impairment were contraindicated to use ROSUVASTATIN. The current study revealed that although ATORVASTATIN was prescribed more frequently than ROSUVASATIN but effectiveness of ROSUVASTAIN was more than that compared to ATORVASTATIN. Most of the patient who reported with Hyperlipidemia to the hospital were prescribed ATORVASTATIN.

Keywords: Comparison, efficacy, and lipid lowering.

[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More